Group 1: Event Overview - The third China International Supply Chain Promotion Expo opened in Beijing on July 16, with over 1,100 representatives from more than 100 countries and regions attending the opening ceremony [1] - The expo's theme is "Linking the World, Creating the Future," featuring six major chains: advanced manufacturing, smart automotive, green agriculture, clean energy, digital technology, and healthy living [1] - A total of 651 enterprises and institutions from 75 countries and regions participated, with 35% of exhibitors being international, indicating a higher level of globalization [1] Group 2: Importance of Cooperation - The current global economic slowdown and rising protectionism are damaging global supply chains, increasing costs, and reducing economic efficiency [2] - Multiple speakers at the expo emphasized the need for cooperation to maintain the stability and smooth operation of global supply chains [2] - The China Council for the Promotion of International Trade (CCPIT) president highlighted the expo's focus on helping businesses find partners and solutions [2] Group 3: Initiatives and Proposals - The "Beijing Initiative" was released, advocating for the maintenance of global supply chain security, innovation-driven development, and deeper cooperation among the global business community [3] Group 4: Platform for Open Cooperation - The expo has evolved into a platform for high-level opening up and global sharing, enhancing trade promotion, investment cooperation, and innovation [4] - Apple showcased its collaboration with three Chinese suppliers, highlighting a $20 billion investment in smart and green manufacturing in China over the past five years [4] Group 5: Innovations and Technologies - Qingdao Beer demonstrated its global supply chain innovation, emphasizing the interconnectedness of its production process [5] - The Beijing Changmu Valley Medical Technology Co., Ltd. showcased its AI-assisted orthopedic surgery robot, marking a significant technological advancement in the healthcare sector [6] - Syngenta Group presented its agricultural innovations, focusing on efficient and sustainable supply chains [6] Group 6: China's Supply Chain Advantages - China plays a crucial role in global supply chains, providing strong support for international cooperation and innovation [7] - Sanofi highlighted its 30 years of localized manufacturing in China, showcasing its end-to-end healthcare ecosystem [7] - Medtronic expressed confidence in China's position as a major medical market and innovation hub, emphasizing its commitment to local value chain development [7]

Group 1 - Suzhou Innovation Investment Group reported significant progress in the first half of the year, with 74 new direct investment projects and an investment amount of 1.56 billion yuan [1] - The group has also established 262 new cooperative fund investment projects, with a total cooperative fund scale of 29.56 billion yuan, exceeding 70% completion for key targets [1] - The majority of new direct investment projects (82.4%) are focused on Suzhou, particularly in the fields of new generation information technology, high-end equipment, and biomedicine [1][2] Group 2 - The investment projects in Suzhou Industrial Park are the most numerous, totaling 25, and are concentrated in advantageous industry clusters such as biomedicine and new materials [2] - Suzhou High-tech Zone has secured 13 major projects, including the representative company Star Key Photonics, showcasing strong collaboration between industry leaders and capital support [2] - The direct investment projects are crucial for building a comprehensive innovation capital network in Suzhou, with full investment coverage across 10 industrial innovation clusters and over 60% coverage of 30 industrial chains [2] Group 3 - Suzhou Innovation Investment Group has organized nearly 50 investment and financing events in the first half of the year, extending outreach to major cities like Shanghai and Beijing to innovate investment models [3] - The second batch of Suzhou strategic new funds has been established, focusing on key sectors such as high-end equipment, biomedicine, and artificial intelligence, with investment progress leading in the province [3] - The group is currently advancing 152 direct investment and sub-fund projects, aiming to continuously inject new vitality into Suzhou's economy [3]

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of a 95.09% stake in Shanghai Lixin Pharmaceutical for approximately $500 million, making Lixin a wholly-owned subsidiary, enhancing its capabilities in the oncology sector [1][2] Group 1: Acquisition Details - The total consideration for the 95.09% stake in Lixin is capped at $950 million, with the net payment amounting to about $500 million after excluding Lixin's cash holdings of $450 million [1] - China National Pharmaceutical previously invested 142 million RMB for a 4.91% stake in Lixin during its C1 round financing [1] Group 2: Pipeline and Technology - Lixin's innovative pipeline includes several promising candidates: 1. LM-299 (PD-1/VEGF bispecific antibody) is in Phase I trials in China and has a global exclusive license agreement with Merck for up to $24 billion in milestone payments [1] 2. LM-305 (GPRC5D ADC) is in Phase I trials globally and has a licensing agreement with AstraZeneca worth up to $545 million [1] 3. LM-108 (CCR8 monoclonal antibody) is in Phase II trials and aims to provide new treatment options for patients who failed PD-1/PD-L1 therapies [1] 4. LM-302 (Claudin 18.2 ADC) is in Phase III trials [1] - Lixin also has several other innovative oncology projects in clinical stages and over ten preclinical bispecific/ADC projects expected to enter clinical trials within 1-2 years [1] Group 3: Strategic Implications - The acquisition of Lixin's differentiated bispecific and ADC technology platforms is expected to significantly enhance China National Pharmaceutical's core competitiveness in the oncology field and may lead to more international opportunities [2] Group 4: Financial Projections - The company forecasts net profits of 4.639 billion, 5.003 billion, and 5.405 billion RMB for 2025-2027, with year-on-year growth rates of 32.56%, 7.84%, and 8.05% respectively, corresponding to PE ratios of 24, 22, and 21 times [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 ● 金宇生物技术股份有限公司（以下简称"公司"）股票于2025年7月15日、7月16日、7月17日连续3个交 易日收盘价格涨幅偏离值累计超过20%。触及《上海证券交易所交易规则》规定的异常波动标准，属于 股票交易异常波动情形。 ● 经公司书面征询本公司第一大股东内蒙古金宇生物控股有限公司（以下简称"生物控股"），截至本公 告披露日，除在指定信息披露媒体及上海证券交易所网站上已公开披露的信息外，不存在应披露而未披 露的信息。 证券代码：600201 证券简称：生物股份 公告编号：临2025-044 金宇生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 公司于本公告披露日同日披露了《金宇生物技术股份有限公司关于获得兽用生物制品临床试验批件的 公告》，全资子公司金宇保灵生物药品有限公司（以下简称"金宇保灵"）收到农业农村部颁发的非洲猪 瘟亚单位疫苗临床试验批件。兽用生物制品在获得临床试验批准后，需要完成临床试验并申报注册， ...

◎刘禹希 记者 费天元 伴随《上海证券交易所科创板上市公司自律监管指引第5号——科创成长层》（下称"科创成长层指 引"）正式发布施行，多家券商第一时间响应落实，陆续上线科创成长层权限开通功能。业内人士表 示，32家未盈利企业首批进入科创成长层，优质科技企业将迎来更加广阔的市场空间。 多家券商上线权限开通功能 科创成长层指引7月13日正式发布并施行，至今不到一周，已有国泰海通、国金证券等多家券商在其交 易App中上线"科创成长层权限开通"功能，投资者按照要求开通权限后即可参与科创成长层股票交易。 另有多家券商表示正在加紧部署相关服务功能。 对于尚未开通科创板交易权限的投资者，需要先开通科创板交易权限，再签署《科创成长层风险揭示 书》，方可参与科创成长层股票交易。科创板权限开通条件如下：一是申请权限开通前20个交易日证券 账户及资金账户内的资产日均不低于50万元；二是近20个交易日内最少有3天资产满足50万元及以上； 三是证券交易经验不低于24个月。 对于已开通科创板交易权限且适当性评估风险等级C4及以上的投资者，仅需要签署《科创成长层风险 揭示书》，即可参与科创成长层股票交易。 为了帮助投资者更直观地区分存量和 ...

Group 1: Investment Opportunities - Vili Zhibo-B (HK02617) has launched its IPO with a subscription rate of approximately 178.91 times on the first day, indicating strong investor confidence in its prospects [1] - Aux Group has refiled its listing application with the Hong Kong Stock Exchange, aiming to enhance brand influence and expand into international markets [2] - Fourth Paradigm (HK06682) plans to place 25.9 million shares at a subscription price of HKD 50.50 per share, raising approximately HKD 1.306 billion for investment in emerging fields like AI and blockchain [3] - October Rice Field (HK09676) expects an adjusted net profit of at least HKD 283 million for the six months ending June 30, 2025, representing a growth of no less than 90% year-on-year due to product innovation and improved sales channels [4] Group 2: Market Performance - The Hang Seng Index closed at 24,498.95, down 0.08% on July 17 [5] - The Hang Seng Tech Index increased by 0.56% to 5,448.85 [5] - The National Enterprises Index fell by 0.09% to 8,853.10 [5]

上交所官网显示，上交所上市审核委员会定于7月18日召开2025年第23次上市审核委员会审议会议，审 议北芯生命的首发事项。 招股书显示，北芯生命是一家专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售的国家高新技 术企业，致力于开发为心血管疾病诊疗带来变革的精准解决方案。 根据安排，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）科创板IPO于7月18日上会接受大 考。这是近期上会的第二家选用科创板第五套标准上市的IPO药企。上交所官网显示，北芯生命于7月8 日披露了二轮问询回复意见，随即获得上会机会，这也体现了科创板审核速度的加快。除了北芯生命以 外，目前还有4家选用第五套上市标准的医药企业正在排队科创板IPO。其中，禾元生物成为科创板重 启第五套标准后第一家上会并通过的企业，目前，禾元生物已提交注册。此外，思哲睿于近期更新提交 相关财务资料，同样处于提交注册阶段。恒润达生进度靠后，目前处于已问询阶段。必贝特则排队时间 最长，已超三年。 | 科创板采用第五套上市标准IPO排队药企情况 | 览(单位:亿元) | | | | --- | --- | --- | --- | | 企业简称 | 目前进展 | ...

Group 1 - The major shareholders of Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. are Yang Zongmeng and Wang Haibo, holding 7.18% and 5.41% of the total shares respectively before the reduction plan [1][2] - Yang Zongmeng planned to reduce his holdings by up to 4,270,800 shares, which is 0.41% of the total share capital, due to personal financial needs [1][2] - The reduction plan was disclosed on June 23, 2025, and the actual reduction took place from July 14 to July 16, 2025 [2][3] Group 2 - Yang Zongmeng reduced his holdings by 10,365,721 shares, representing 1.00% of the total share capital, with a total amount of approximately 92.79 million yuan [2][3] - Wang Haibo reduced his holdings by 4,270,722 shares, which is 0.41% of the total share capital, with a total amount of approximately 38.59 million yuan [3] - After the reductions, Yang Zongmeng's remaining shares are 64,009,773, which is 6.18% of the total share capital, while Wang Haibo's remaining shares are 51,828,605, which is 5.00% [3]

7月份以来，已有多只科技主题基金提前结束募集，认购热情持续升温。从科创板ETF到人工智能主题 产品，资金正以超预期速度布局科技赛道。这一现象不仅折射出市场对成长型资产的偏好升温，更揭示 出在政策红利与技术突破共振下，科技创新板块正成为中长期资金配置的核心方向。 朱润康认为，随着科技主题公募基金受到踊跃认购，科技相关主题ETF有望持续获得资金注入。需要注 意的是，投资者应当重点关注那些具备技术壁垒、商业模式清晰且业绩确定性强的优质企业。 今年1月份，工业和信息化部明确提出，"加快研究出台促进数字产业高质量发展的文件""打造5G应 用'扬帆'和'5G+工业互联网'升级版，加快新一代信息技术全方位全链条普及应用"等。在多位业内人士 看来，相关政策导向直接强化了市场对半导体、人工智能等硬科技领域的长期信心。 "今年以来，顶层设计持续加码，政策支持与产业趋势形成共振，为科技板块上涨奠定了基础。"晨星 (中国)基金研究中心高级分析师李一鸣在接受《证券日报》记者采访时表示，在政策推动下，半导体、 机器人等领域实现突破发展，例如诸多科创企业不断实现技术突破，吸引资金通过基金产品提前布局产 业链机会。 与此同时，流动性环境也持 ...

Core Viewpoint - The article emphasizes the significance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, particularly in China, as part of its manufacturing strength initiatives. The upcoming SynBioCon 2025 conference aims to explore the development trends in biomanufacturing and foster collaboration among industry leaders, experts, and investors [1]. Group 1: Conference Overview - The SynBioCon 2025 will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing, along with four application areas: green chemicals and new materials, future food, future agriculture, and beauty ingredients [1]. - The conference will gather international leading companies, industry experts, government representatives, and capital to discuss the trends and innovations in the biomanufacturing sector during the "14th Five-Year Plan" period [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by institutions such as Peking University Ningbo Institute of Ocean Medicine and Ningbo Enzyme Sai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - Key highlights include forums and closed-door discussions on biomanufacturing development trends, sharing of innovative technologies and values, and over 100 financing project roadshows to discover new cooperation opportunities [5]. - The event will feature a high-level closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [9]. Group 4: Agenda and Special Sessions - The first day will include a high-level closed-door seminar and a youth innovation technology forum aimed at discovering potential teams and technologies in biomanufacturing [12]. - The second and third days will feature a macro forum on biomanufacturing, specialized sessions on green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty ingredients [13][15][18]. Group 5: Topics of Discussion - Discussions will cover various topics such as the development of bio-based materials, new carbon source biomanufacturing, and the application of AI in enzyme discovery and industrial fermentation processes [16][17]. - The conference will also explore the biomanufacturing of high-value food ingredients, natural flavors, and the application of biotechnology in cosmetics [20].